eFFECTOR Therapeutics Inc... (EFTRW)
eFFECTOR Therapeutics Statistics
Share Statistics
eFFECTOR Therapeutics has 4.7M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 4.7M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is null and the forward PE ratio is null.
| PE Ratio | null |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -4.41 |
| P/FCF Ratio | null |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for eFFECTOR Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.77, with a Debt / Equity ratio of null.
| Current Ratio | 0.77 |
| Quick Ratio | 0.77 |
| Debt / Equity | null |
| Debt / EBITDA | -0.58 |
| Debt / FCF | -0.66 |
| Interest Coverage | null |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.56M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.8, so eFFECTOR Therapeutics's price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 39.56 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -22.92M |
| Operating Income | -33.84M |
| Net Income | -35.81M |
| EBITDA | -33.73M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -16.37 |
Balance Sheet
The company has 14.88M in cash and 19.45M in debt, giving a net cash position of -4.57M.
| Cash & Cash Equivalents | 14.88M |
| Total Debt | 19.45M |
| Net Cash | -4.57M |
| Retained Earnings | -179.38M |
| Total Assets | 27.13M |
| Working Capital | 681K |
Cash Flow
In the last 12 months, operating cash flow was -29.55M and capital expenditures -97K, giving a free cash flow of -29.65M.
| Operating Cash Flow | -29.55M |
| Capital Expenditures | -97K |
| Free Cash Flow | -29.65M |
| FCF Per Share | -13.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EFTRW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for EFTRW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -13.59 |
| Piotroski F-Score | 2 |